Takeda Pharmaceutical (TAK) Cash from Investing Activities (2018 - 2026)

Takeda Pharmaceutical's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$369.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 186.78% year-over-year to -$369.9 million in Q1 2026; TTM through Mar 2026 was -$2.4 billion, a 0.83% decrease from a year earlier, with the FY2026 full-year figure at -$2.5 billion, down 1.77% from the prior year.
• Cash from Investing Activities grew to -$369.9 million in Q1 2026 per TAK's latest filing, from -$1.5 billion in the prior quarter.
• Across five years, Cash from Investing Activities topped out at -$129.0 million in Q1 2025 and bottomed at -$3.3 billion in Q1 2023.
• The 5-year median for Cash from Investing Activities is -$419.5 million (2023), against an average of -$759.0 million.
• Across the five-year window, Cash from Investing Activities tumbled 1402.64% in 2023 and surged 87.48% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$330.5 million in 2022, then tumbled by 54.08% to -$509.2 million in 2023, then sank by 49.27% to -$760.1 million in 2024, then tumbled by 96.45% to -$1.5 billion in 2025, then jumped by 75.22% to -$369.9 million in 2026.
• Per Business Quant, the three latest TAK Cash from Investing Activities figures stand at -$369.9 million (Q1 2026), -$1.5 billion (Q4 2025), and -$326.7 million (Q3 2025).